TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04898283: Prospective, Multicentre, Doubleblind, Placebo-controlled RCT to Evaluate Efficacy and Safety With SC Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitised to Gras

Sponsor: Inmunotek S.L. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,757,600

Rescue Site Savings

+$7,740,420

Unlock Full NCT04898283 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04898283 Rescue Dossier →